PD-1 controls differentiation, survival, and TCR affinity evolution of stem-like CD8+ T cells

Area of Science:

• Immunology
• Cancer Biology
• T cell biology

Background:

• Stem-like cytotoxic T cells are crucial for effective cancer immunotherapy.
• Tumor-draining lymph nodes are key sites for generating these stem-like cells.
• Understanding factors maintaining T cell stemness is vital for improving immunotherapies.

Purpose of the Study:

• To identify niches in tumor-draining lymph nodes supporting stem-like CD8+ T cells.
• To investigate the role of antigen signaling and PD-1 in maintaining T cell stemness.
• To explore the impact of PD-1 blockade on stem-like T cell populations.

Main Methods:

• Advanced 3D multiplex immunofluorescence imaging.
• In vivo studies of T cell proliferation and self-renewal.
• Analysis of T cell receptor (TCR) signaling and PD-1 pathway interactions.

Main Results:

• Antigen-presentation niches in lymph nodes support stem-like TCF-1+PD-1+SLAMF6hi CD8+ T cells.
• Prolonged antigen engagement, not just initial priming, sustains stem-like T cell self-renewal.
• The PD-1 pathway fine-tunes TCR signaling, promoting high-affinity stem-like clone expansion.
• PD-1 blockade disrupts this signaling, causing effector differentiation or death of avid stem-like cells.

Conclusions:

• TCR ligand affinity, PD-1 signaling, and T cell stemness are intricately linked.
• PD-1 blockade may offer short-term benefits at the expense of long-term efficacy by depleting high-affinity stem-like precursors.
• Findings challenge current understanding of T cell responses in cancer immunotherapy.